2014 Doctors FDA Sales 
pharmaphorum
NOVEMBER 11, 2022
Viehbacher led Sanofi between 2008 and 2014 and has decades of experience with both large pharmaceutical companies and small biotechs. However, in 2014 Sanofi fired Viehbacher over a boardroom fight regarding his management. Biogen’s shares rose 2.4% to $289.01 in pre-market trading following the announcement.
pharmaphorum
DECEMBER 29, 2022
The case revolves around allegations that Novartis made an agreement in 2011 with Par Pharmaceutical when Exforge (valsartan/amlodipine) was nearing the end of its patent life that was designed to keep Par’s generic version of the drug off the market until 30 September, 2014.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
SEPTEMBER 27, 2022
Biogen has finalised a $900 million payment to settle a whistleblower lawsuit claiming that it paid kickbacks to US doctors to prescribe its multiple sclerosis drugs. That resulted in false claims for payment being submitted to the government healthcare programs Medicare and Medicaid, it alleged. .”
Pharmaceutical Technology
OCTOBER 5, 2022
Between 2009 and 2014, the time period of Biogen’s alleged misconduct, the standard of care for MS involved the use of Biogen’s immunomodulatory drugs such as Avonex (Interferon beta-1a), Tecfidera (dimethyl fumarate), and Tysabri (natalizumab). At the same time, companies need to prioritize their compliance programs.
European Pharmaceutical Review
AUGUST 23, 2022
On- or in-dose authentication means that a security measure or anticounterfeit feature is integrated with the dosage form itself, offering product verification and traceability embedded into each medicine, rather than on the secondary package” WHO estimates that >50 percent of the drugs for sale on the internet are fake.
Evolve Your Success
JANUARY 23, 2024
In the changing balance between innovation and tradition, medical sales succeeds with personal connection, persistence, and the commitment to link technology and patient care. For today’s episode, we have Edouard Saget to discuss the big question: Will AI replace medical sales workforce and surgeons? Tune in to find out!
Pharmaceutical Technology
JANUARY 6, 2023
The agreement outlined that Par would keep its generic equivalent off the market for as many as two years, delaying the generic launch till September 30, 2014. In a press release, the company said a generic launch would damage sales in FY 2023 by $300,000. These actions allegedly led to the extension of Novartis’ patents.
Expert insights. Personalized for you.
40 
Let's personalize your content